Upgrade to SI Premium - Free Trial

Jazz Pharmaceuticals (JAZZ) PT Lowered to $190 at Stifel Following 4Q

March 1, 2017 9:00 AM
Stifel lowered its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $190.00 (from $200.00) while maintaining a Buy rating.Analyst Annabel ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Next Articles